2,4-二氯嘧啶 、 4-氟-3-甲基苯胺 以
异丙醚 为溶剂,
以3.8 g of expected product are obtained (melting point=130-131° C.) (trituration in isopropyl ether)的产率得到(2-chloropyrimidin-4-yl)(4-fluoro-3-methyl-phenyl)amine
参考文献:
名称:
N,N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS
N,N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS
申请人:BABIN Didier
公开号:US20100093668A1
公开(公告)日:2010-04-15
The disclosure relates to a compound of formula (I):
wherein R, R1, R2, R3, R4, R5, R6 and Z are as defined in the specification, to compositions containing them, to processes for preparing them, and to their use in the treatment or prevention of conditions capable of being modulated by the inhibition of the activity of protein kinases.
Novel 2,4-Dianilinopyrimidine Derivatives, the Preparation Thereof, Their Use as Medicaments, Pharmaceutical Compositions and, in Particular, as IKK Inhibitors
申请人:Bosch Michael
公开号:US20080269170A1
公开(公告)日:2008-10-30
The disclosure relates to compounds of formula (I):
wherein R1-R5, A and Y are as defined in the disclosure, to compositions comprising said compounds, and to processes for making and methods of using the same.
Pyrimidine-2, 4-diamine JAK2 Kinase inhibiting anti-inflammation use
申请人:Hwang Soo-In
公开号:US20100029675A1
公开(公告)日:2010-02-04
A method of treatment or prevention of Castleman's disease, atherosclerosis, coronary artery disease, peripheral edema, peripheral vascular disease, glaucoma, and wet or dry age-related macular degeneration (AMD), asthma; chronic bronchitis; chronic obstructive pulmonary disease; adult respiratory distress syndrome; infant respiratory distress syndrome; cough; chronic obstructive pulmonary disease in animals; adult respiratory distress syndrome; ulcerative colitis; Crohn's disease; hypersecretion of gastric acid; bacterial, fungal, or viral induced sepsis or septic shock; endotoxic shock; laminitis or colic in horses; spinal cord trauma; head injury; neurogenic inflammation; pain; reperfusion injury of the brain; psoriatic arthritis; rheumatoid arthritis; alkylosing spondylitis; osteoarthritis; inflammation; or cytokine-mediated chronic tissue degeneration comprises the step of administering a therapeutically effective amount, or a prophylactically effective amount, of a compound having the following structure (I):
NOUVEAUX DERIVES DE 2,4-DIANILINOPYRIMIDINES, LEUR PREPARATION, A TITRE DE MEDICAMENTS, COMPOSITIONS PHARMACEUTIQUES ET NOTAMMENT COMME INHIBITEURS DE IKK
申请人:Sanofi-Aventis
公开号:EP1904479A2
公开(公告)日:2008-04-02
DERIVES DE N, N' - 2, 4 -DIANILINO PYRIMIDINES, LEUR UTILISATION COMME INHIBITEURS DE IKK, LEUR PREPARATION ET LEUR COMPOSITIONS PHARMACEUTIQUES